Olatoyosi Odenike, MD
David A. Garcia, MD
As co-chairs of the Education Program, what were your goals in putting the program together?
Dr. Odenike: We wanted to make sure that the program was as contemporary and as comprehensive as possible. We are in a very fast-paced, ever-changing world in hematology, and we wanted to make sure the audience was brought up to speed on some of the most exciting developments in today’s era.
Dr. Garcia: I would totally agree with that, and I would add that while the ASH Annual Meeting Education Program already has a strong tradition of superb speakers who are internationally recognized experts but also great teachers and are covering topics that have practice-changing information or updates, we thought it was especially important to have a fantastic program this year because there’s an enthusiastic push by ASH to get folks to attend the meeting in person, and we really wanted to make it worth their while to come to New Orleans and be part of this exciting program.
Bone Marrow Failure Syndromes: Diagnostic Principles in 2022
Sunday, December 11, 2022, 4:30 p.m. – 5:45 p.m., Ernest N. Morial Convention Center, 260-262, Level 2
Debate: Most/All Patients With Acquired (Immune) Thrombotic Thrombocytopenic Purpura Receive Caplacizumab
Monday, December 12, 2022, 10:30 a.m. – 11:45 a.m., Ernest N. Morial Convention Center, 295-296, Level 2
Can you speak to how this year’s program differs from that of past Annual Meetings?
Dr. Odenike: ASH has always had a diverse lineup in terms of the length and breadth of hematology. We did our best to represent and improve upon that. We tried to make sure there was also broad representation in the speaker lineup. I think ASH does that all the time, to be honest. The Spotlight Sessions are always very interesting. ASH tries to do something different each year, and this year’s Spotlight Sessions are no exception in that regard. There is a lot that will keep the audience very excited and engaged at this meeting.
Dr. Garcia: I don’t know how much it differs from prior meetings, but I’d like to think that we struck a good balance between emphasizing the science behind the clinical decision-making but also making sure the real-world questions or controversies facing practicing doctors get addressed across the whole Education Program. The Spotlight Sessions especially allow us to go deeper into controversies or areas of uncertainty that are a good forum for debate or presentation of differing viewpoints.
Did you implement any lessons learned from the 2021 hybrid program to help optimize the hybrid format?
Dr. Odenike: There was a lot of feedback solicited from attendees at last year’s meeting as well as from folks who were involved in the Program Committee. One change was to have the speakers and the chairs attend in person and to not have sessions moderated remotely because that did not make for as smooth a program as one would have liked last year. So just tidbits like that, using the feedback from last year to improve this year’s program as much as possible while still trying to preserve the flexibility that the hybrid program offers.
What sessions do you want to attend?
Dr. Odenike: I want to attend every single session. ASH is a great meeting, and there is just so much to learn from. The fact that this is hybrid is also wonderful because one thing every ASH attendee has experienced is when there’s this really great education session going on and then there’s an equally great scientific session at the same time, but how can you be in both places at once? The hybrid format solves that since you can go back and re-live those sessions. I don’t think I am able to pick favorites because everything that’s on the menu has been very thoughtfully crafted and planned out and we are very excited to be able to give the attendees their due.
Immunotherapies for Myeloid Neoplasms:
Are We Ready for Primetime?
Monday, December 12, 2022, 2:45 p.m. – 4:00 p.m., Ernest N. Morial Convention Center, New Orleans Theater AB, Level 2
New Horizons for Histiocyte Disorders
Sunday, December 11, 2022, 4:30 p.m. – 5:45 p.m., Ernest N. Morial Convention Center, 275-277, Level 2
Can you talk about the planning process and how you collaborated?
Dr. Garcia: ASH does a great job of providing us with an advisory board of content experts within our respective “halves” of hematology, if you will. I was the co-chair for the classical (non-malignant) hematology portion of the program and had advisors who were experts and suggesting topics in bone marrow failure syndromes, sickle cell disease and other hemoglobinopathies, red cell disorders, coagulation, and transfusion medicine.
Point/Counterpoint: The Case For/Against Thrombophilia Testing in Many/Most Adults With Unprovoked Thrombosis
Monday, December 12, 2022, 2:45 p.m. – 4:00 p.m., Ernest N. Morial Convention Center, 288-290, Level 2
Survivorship in Adult Patients With Lymphoma
Sunday, December 11, 2022, 4:30 p.m. – 5:45 p.m., Ernest N. Morial Convention Center, Great Hall A/D, Level 1
Dr. Odenike: It’s really challenging in our never-ending world where there’s so many advances being made all the time for one human to be an expert, like in all of classical hematology or all of malignant hematology, which is the part of the program that I co-chaired. My advisory panel spanned the breadth of all the main domains in malignant hematology, so myeloid malignancies, lymphoid malignancies, myeloma, transplant, and even pediatric hematology, which is a big one that many of us who are not in that world don’t know as much about. It’s a testament to the wonderful volunteers and staff who make up ASH that we can put this program together. Though David and I were the co-chairs of the program, we had a lot of help with the heavy lifting.
Underrepresented Minorities in Clinical Trials for Hematologic Malignancies: What’s the Data on the Data?
Monday, December 12, 2022, 10:30 a.m. – 11:45 a.m., Ernest N. Morial Convention Center, R06-R09, Level 2
Acute Myeloid Leukemia: Improving Outcomes in Challenging Subsets
Sunday, December 11, 2022, 9:30 a.m. – 10:45 a.m., Ernest N. Morial Convention Center, Great Hall B/C, Level 1
What else would you like attendees to know about the program?
Dr. Odenike: We also had a community as well as a scientific advisor, which I think was important in making sure that the program was relevant to the everyday practicing hematologist, while at the same time being scientifically sound.
Dr. Garcia: That’s an important thing to emphasize, that on each of our respective advisory panels, we had a community-based, practicing hematologist giving us input. In my program in particular, my advisor made a couple of really concrete suggestions that ended up translating into sessions that we might not have otherwise done or done exactly the way they ended up.